@article {Fabbri19007161, author = {Chiara Fabbri and Siegfried Kasper and Alexander Kautzky and Joseph Zohar and Daniel Souery and Stuart Montgomery and Diego Albani and Gianluigi Forloni and Panagiotis Ferentinos and Dan Rujescu and Julien Mendlewicz and Rudolf Uher and Cathryn M. Lewis and Alessandro Serretti}, title = {A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping}, elocation-id = {19007161}, year = {2019}, doi = {10.1101/19007161}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Treatment-resistant depression (TRD) occurs in \~{}30\% of patients with major depressive disorder (MDD) but the genetics of TRD was previously poorly investigated.Whole exome sequencing and genome-wide genotyping were performed in 1320 MDD patients. Response to the first pharmacological treatment was compared to non-response to one treatment and non-response to two or more treatments (TRD). Differences in the risk of carrying damaging variants were tested. A score expressing the burden of variants in genes and pathways was calculated weighting each variant for its functional (Eigen) score and frequency, considering rare variants only and rare + common variants. Gene- and pathway-based scores were used to develop predictive models of TRD and non-response using gradient boosting in 70\% of the sample (training) which were tested in the remaining 30\% (testing), evaluating also the addition of clinical predictors. Independent replication was tested in STAR*D and GENDEP using exome array-based data.After quality control 1209 subjects were included. TRD and non-responders did not show higher risk to carry damaging variants compared to responders. Genes/pathways associated with TRD included those modulating cell survival and proliferation, neurodegeneration and immune response. Significant prediction of TRD vs. response was observed in the testing sample which was improved by the addition of clinical factors. Some models were replicated, with a weaker prediction, in STAR*D and GENDEP when considering also clinical factors and in the extremes of the genetic score distribution.These results suggested relevant biological mechanisms implicated in TRD and a new methodological approach to the prediction of TRD.Competing Interest StatementDr. Souery D. has received grant/research support from GlaxoSmithKline and Lundbeck; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Lundbeck. Prof. Montgomery S. has been a consultant or served on Advisory boards: AstraZeneca, Bristol Myers Squibb, Forest, Johnson \& Johnson, Leo, Lundbeck, Medelink, Neurim, Pierre Fabre, Richter. Prof. Kasper S. received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Prof. Zohar J. has received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche, and has served on speakers{\textquoteright} bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. Prof. Mendlewicz J. is a member of the Board of the Lundbeck International Neuroscience Foundation and of Advisory Board of Servier. Prof. Serretti A. is or has been consultant/speaker for: Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. The other authors declare no conflict of interest. Cathryn Lewis is a member of the R\&D SAB of Myriad Neuroscience.Clinical Trialcross-sectional observational study.Funding StatementChiara Fabbri is supported by a Marie Sk{\l}odowska-Curie Actions Individual Fellowship funded by the European Community (EC Grant agreement number: 793526; project title: Exome Sequencing in stages of Treatment Resistance to Antidepressants - ESTREA). Cathryn M. Lewis is part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. Dr Rudolf Uher is supported by the Canada Research Chairs Program. This study was supported by an unrestricted grant from Lundbeck for the Group for the Study of Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. All authors were actively involved in the design of the study, the analytical method of the study, the selection and review of all scientific content. All authors had full editorial control during the writing of the manuscript and approved it.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableIndividual-level data or summary statistics is not publicly available for GSRD and GENDEP, however raw genotypes and phenotypes of these samples are available to Psychiatric Genomic Consortium (PGC) analysts (https://www.med.unc.edu/pgc/) within approved projects. Individual-level data is publicly available for STAR*D through the NIMH genetics website (https://www.nimhgenetics.org), after submission of a research project and access authorization. https://www.nimhgenetics.org}, URL = {https://www.medrxiv.org/content/early/2019/09/20/19007161}, eprint = {https://www.medrxiv.org/content/early/2019/09/20/19007161.full.pdf}, journal = {medRxiv} }